CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption

Key Takeaways CRISPR Therapeutics (CRSP) reported a second-quarter 2025 loss of $2.40 per share, which was wider than the year-ago period's loss of $1.49. The increased loss was attributable to the payment of $96.3 million (recorded as acquired in-process R&D expenses) made to Sirius Therapeutics as part of a strategic collaboration agreement signed in May. Excluding this special item, the adjusted loss stood at $1.29 per share, narrower than the Zacks Consensus Estimate of a loss of $1.47. No such expense ...